Interview with John Norman, Country Manager, Nycomed South Africa
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
Address: 1 Libertas Road
Cnr Main Road and Sloane Street
Bryanston, Johannesburg
2191,South Africa
Tel: +27 (0) 11 514 3000
Web: http://www.takeda.co.za/za/
The South African arm of Nycomed has its origins in 1996 when two German companies, Byk Gulden and Madaus AG entered into a joint venture in South Africa and Byk Madaus was created. All products were managed in one combined portfolio and came from either Byk Gulden, Madaus or were in-licenced from other companies. Packaging, warehousing and distribution operations were carried out at a warehouse facility in Midrand.
In 2001, the company outsourced its distribution to PHD.
In 2002, Altana Pharma was launched when Altana bought out the Byk portion of the Byk Madaus joint venture.
In 2003 a further name change took place and the company became the South African joint venture known as Altana Madaus. It was during this period that a separate OTC and Rx division were launched, the Midrand facility was sold and the company moved from Midrand to Woodmead.
In 2007 Nycomed GmbH acquired Altana Pharma and Rottapharm acquired Madaus GmbH. A further name change took place and the local company became known as Nycomed Madaus.
In 2008, Nycomed GmbH acquired the Madaus 50% share of the joint venture and the South African business now falls under the sole control of the Nycomed group of companies.
The South African product range encompasses both licensed and in-licensed OTC (Over the Counter) and Rx (prescription) products. These products are marketed and distributed nationally.
The Rx* product range covers the following treatment areas:
Respiratory
Anti-Epileptic
Urinary Tract
Iron
Liver
Gastro Intestinal
Pain and Inflamation
* In terms of South African legislation, scheduled products may not be marketed to the public and the brands have therefore not been mentioned on this website
The OTC product range encompasses the following treatment areas and products:
Laxatives – Agiolax® and Agiobulk®
Tranquiliser – Biral®
Pain and Inflammation – Empaped®, Reparil®, Dona®
Vitamin and Mineral – Emvit®, Emvit®.M, Emvit® Cal-D3, Magnesit®
Iron – Ferrimed®
Sun care – Piz Buin®
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of…
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It is a purely romantic…
Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of employees for multinational organizations.…
You were recently appointed at the head of Eli Lilly South African operations. What is the specific mission you have been given? Eli Lilly South Africa is in an interesting…
An emerging country with a dynamic market, South Africa is widely seen as the gateway to Africa. From major multinational pharmaceutical corporations to burgeoning local generic companies, a wide…
We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are interviewing you today at the head…
Dr Pillay, South Africa recently became a member of BRICS. With this distinction, we need to improve our healthcare outcomes relative to other BRICS countries. All countries have challenges with…
The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an…
Since we that came to South Africa in 2005 and interviewed you, what have been the main changes both in the market place, and within Sanofi as an organization? The…
In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new…
Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio?…
See our Cookie Privacy Policy Here
